Screening for pulmonary hypertension warranted in TKI-treated patients with CML

Key clinical point: Pulmonary hypertension (PH) is common in patients with chronic myeloid leukemia (CML) treated with tyrosine kinase inhibitors (TKI), warranting careful screening for PH in this patient population.

Major finding: Overall, 10.7% of patients undergoing transthoracic echocardiography (TTE) during TKI treatment were diagnosed with PH. Dasatinib treatment (odds ratio [OR] 8.2; P = .03), age above 60 years (OR 12.3; P = .04), and presence of cardiopulmonary symptoms/signs (OR 36.1; P = .001) were significant risk factors for PH.

Study details: Findings are from a retrospective analysis of 112 patients with CML who underwent TTE during TKI treatment.

Disclosures: This study was funded by the Research Fund of Chungnam National University Hospital and the Bio and Medical Technology Development Program of the National Research Foundation of Korea. The authors declared no conflict of interests.

Source: Song IC et al. Medicine. 2021 Aug 20. doi: 10.1097/MD.0000000000026975.

Key clinical point: Pulmonary hypertension (PH) is common in patients with chronic myeloid leukemia (CML) treated with tyrosine kinase inhibitors (TKI), warranting careful screening for PH in this patient population.

Major finding: Overall, 10.7% of patients undergoing transthoracic echocardiography (TTE) during TKI treatment were diagnosed with PH. Dasatinib treatment (odds ratio [OR] 8.2; P = .03), age above 60 years (OR 12.3; P = .04), and presence of cardiopulmonary symptoms/signs (OR 36.1; P = .001) were significant risk factors for PH.

Study details: Findings are from a retrospective analysis of 112 patients with CML who underwent TTE during TKI treatment.

Disclosures: This study was funded by the Research Fund of Chungnam National University Hospital and the Bio and Medical Technology Development Program of the National Research Foundation of Korea. The authors declared no conflict of interests.

Source: Song IC et al. Medicine. 2021 Aug 20. doi: 10.1097/MD.0000000000026975.

Key clinical point: Pulmonary hypertension (PH) is common in patients with chronic myeloid leukemia (CML) treated with tyrosine kinase inhibitors (TKI), warranting careful screening for PH in this patient population.

Major finding: Overall, 10.7% of patients undergoing transthoracic echocardiography (TTE) during TKI treatment were diagnosed with PH. Dasatinib treatment (odds ratio [OR] 8.2; P = .03), age above 60 years (OR 12.3; P = .04), and presence of cardiopulmonary symptoms/signs (OR 36.1; P = .001) were significant risk factors for PH.

Study details: Findings are from a retrospective analysis of 112 patients with CML who underwent TTE during TKI treatment.

Disclosures: This study was funded by the Research Fund of Chungnam National University Hospital and the Bio and Medical Technology Development Program of the National Research Foundation of Korea. The authors declared no conflict of interests.

Source: Song IC et al. Medicine. 2021 Aug 20. doi: 10.1097/MD.0000000000026975.